Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domai…
Biotechnology
US, Cambridge [HQ]
Ratios
5 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross Margin | - - | - - | - - | - - | - - | |
| Profit Margin | - - | - - | - - | - - | - - | |
| Operating Margin | - - | - - | - - | - - | - - | |
|
EPS Growth
|
- - | -25.00 | -220.00 | -54.17 | -46.62 | |
| EPS USD | -24.00 | -30.00 | -96.00 | -148.00 | -217.00 | |
| Return on Assets (ROA) | -356.12 | -136.73 | -15.77 | -15.20 | -17.23 | |
| Return on Equity (ROE) | 68.43 | 46.47 | -16.26 | -15.84 | -18.02 | |
| Return on Invested Capital (ROIC) | 86.70 | 62.24 | -16.07 | -16.67 | -21.34 | |
| Solvency | ||||||
| Equity Ratio | -500 | -200 | - - | - - | - - | |
| Debt/Assets | 160.43 | 39.38 | - - | - - | - - | |
| Debt/Equity | -30.83 | -13.38 | - - | - - | - - | |
| Debt/EBITDA | 8.14 | 47.90 | 149.57 | 280.82 | 224.35 | |
|
Debt/Capitalization
|
-44.57 | -15.45 | - - | - - | - - | |
| Long-Term Debt/Capitalization | -14.41 | -7.68 | - - | - - | - - | |
| Interest Debt per Share USD | 0.11 | 0.09 | - - | 0.09 | 0.40 | |
| Debt Growth | - - | 2.85 | -100.00 | - - | - - | |
| Liquidity | ||||||
| Current Ratio | 76.21 | 243.06 | 3,307.48 | 2,453.63 | 2,282.90 | |
| Quick Ratio | 69.32 | 235.89 | 3,278.83 | 2,423.71 | 2,262.22 | |
| Cash Ratio | 69.32 | 235.89 | 779.86 | 1,241.24 | 1,053.91 | |
| Operating Cash Flow Ratio | -200 | -300 | -400 | -300 | -300 | |
| Turnover | ||||||
| Inventory Turnover | - - | - - | - - | - - | - - | |
| Receivables Turnover | - - | - - | - - | - - | - - | |
| Payables Turnover | - - | - - | - - | - - | - - | |
|
Asset Turnover
|
- - | - - | - - | - - | - - | |
| Fixed Turnover | - - | - - | - - | - - | - - | |
| Coverage | ||||||
| Interest Coverage | - - | - - | - - | -2,024.17 | -642.34 | |
| Asset Coverage | - - | 300 | - - | - - | - - | |
| Cash Flow Coverage (CFGR) | -181.18 | -356.61 | - - | - - | - - | |
| EBITDA Coverage | - - | - - | - - | -2,000 | -600 | |
| Dividend Coverage | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||
| Dividend Yield | - - | - - | - - | - - | - - | |
| Earnings Yield | -1.30 | -1.61 | -5.04 | -4.96 | -2.95 | |
|
Price/Earnings (P/E)
|
-7,666.39 | -6,219.60 | -1,984.51 | -2,016.66 | -3,394.62 | |
| Price/Earnings Growth (PEG) | - - | -248.78 | -9.02 | -37.23 | -72.81 | |
|
Price/Book (P/B)
|
-5,246.43 | -2,890.29 | 322.62 | 319.48 | 611.60 | |
| Price/Tangible Book (P/TB) | -5,246.43 | -2,890.29 | 322.62 | 319.48 | 611.60 | |
| Price/Sales (P/S) | - - | - - | - - | - - | - - | |
|
Price/Cash Flow (P/CF)
|
-9,392.31 | -6,056.09 | -2,298.96 | -2,276.61 | -4,295.87 | |
| Price/Free CF (P/FCF) | -9,392.31 | -6,056.09 | -2,298.96 | -2,276.61 | -4,295.87 | |
| Price/Operating CF (P/OCF) | -9,392.31 | -6,056.09 | -2,298.96 | -2,276.61 | -4,295.87 |